Verdict: WATCH (confidence 3/5) · price $8.55 on 2026-10-09 · tranches $7.00 / $5.00 / $3.50 · trim above $20 Premier Protein is a real brand with ROIC of 34–46% and sales that grew from $1.0B (2020) to $2.3B (2025). But FY26 adjusted EBITDA is now guided to $275–295M (about a 12% margin, from 18% last year's Q4), and $1.1B of debt is 5 years of TTM FCF (the screen's debt flag). The screen's $30 Payback and $15 Ten Cap use cash flow from before the squeeze. On trough margins the shares are roughly fairly priced, not cheap. Research, not advice.
R · Radar
- Screen: BUY, tier B, rank 5.55, 3 methods agree, 76% below the 52-week high, marker score 0.50, flag "debt > 3 years of FCF". 1 insider buy ($0.02M, token). No gurus, no Radar items. Next report ~2026-11-03.
- Street: 12 analysts, rating 2.07/5 (2 strong buy, 6 buy, 5 hold, 0 sell, 1 strong sell), targets $10 / $14.71 / $20 (as of 2026-10-10). Street EPS: −52% this year, +27% next. Signal: agree (the street and the screen both see cheap). The street's mean is below the screen's MOS ($21.30) and I do not raise any price because of it. The street sees a margin trough; I can't confirm one.
U · Understand
- The business in one sentence: BellRing sells ready-to-drink protein shakes and powders (Premier Protein, Dymatize) mostly through big retailers such as Costco, Walmart and Sam's Club.
- Money: FY25 sales $2.32B (+16%). FY26 Q3 sales +4% [1][2]. Segment and customer concentration: not confirmed this run; retail concentration (Costco and Walmart) is a known risk, to be checked in the 10-K. Rivals: Fairlife (Coca-Cola), Muscle Milk, Ensure/Boost, private-label protein shakes.
- Weather: consumer staples, protein demand tailwind (including GLP-1 users), dairy-protein costs, freight, tariffs, and trade spending to keep retail shelf space [2].
- Circle of competence: 3/5. Simple product. Still to learn: contract terms and customer shares, the cost of milk protein, why margin fell about six points.
L · Love (moat and management)
- Moat: brand and shelf position, with scale in co-manufacturing. Replication test: a giant such as Coca-Cola (Fairlife) already competes; private label is cheaper. Disappears test: shoppers would notice, but could switch. Pricing power: untested. The company plans double-digit price rises on Premier Protein in FY27 [2]; if volume holds, that is evidence, if not, it is a warning. ROIC (
history_usd): 30.6% (2022) → 46.3% (2024) → 42.4% (2025), well above 10%, but based on a small equity base. - Management: spun out of Post in 2022; debt grew to $1.08B (2025) from $0.83B (2024) while 2025 shares fell 128.5M from 132.3M; the screen's share count is ~118M. A new president and CEO, Mike Axelrod, joined shortly before the Q3 call [2]. Proxy, buyback prices and insider buying: not found (one $0.02M buy is token). FCF $225M TTM (screen) vs net debt $1,085M.
- Values: nothing to flag; protein food products.
- Would I buy the whole company at this price? Maybe. Equity ~$1.0B plus net debt ~$1.1B is ~$2.1B enterprise value, about 7.3x guided FY26 EBITDA (midpoint $285M), a fair price for a margin-hit brand, not a bargain.
E · Event
- What happened: Q3 FY26 (4 Aug): adjusted EBITDA margin came in below guidance, so the full-year outlook was cut to adjusted EBITDA of $275–295M (~12% margin); Q4 expected flat in sales with ~10% margin on inventory-related items, freight, tariffs and trade spending [2][3]. CEO change. 2027 guidance comes with the Q4 call (November).
- Event checks (METHOD 7):
- Known: ✔ margin squeeze and a new CEO.
- Easy to find: ✔.
- Needs at least a year: ✔.
- Resolves within ~3 years: ? depends on pricing sticking and costs easing.
- No new debt needed: ✔ operations fund themselves, but existing debt limits any buyback.
- You would own it for life: ? the brand is strong, the economics are in doubt.
- Event or problem? A possible event (cost and mix squeeze at a good brand), but the debt, the CEO change and untested pricing power stop me calling it one yet. Not cheap at a high, so no value-trap flag.
R · Reduce basis (tranches only, no options)
| Tranche | Price | Basis | Status |
|---|---|---|---|
| 1 | $7.00 | Trough Ten Cap (~$5, see below) plus ~$2 for partial margin recovery; judgement, not arithmetic | Not yet (price $8.55) |
| 2 | $5.00 | Trough Ten Cap: FCF ~$170M (derived: EBITDA $285M less ~$65M interest (unconfirmed), ~$45M tax, ~$5M capex); (10×$170M − $1.085B)/118M ≈ $5.2 | Not triggered |
| 3 | $3.50 | trough case with a further 15% EBITDA cut | Not triggered |
The screen's $30.10 / $21.30 / $15.09 plan uses TTM owner earnings ($287M) and 15% growth; with EBITDA at $285M before interest, those aren't reached. Equal dollar tranches; keep dry powder for a further ~50% fall. Stop buying above $7. Trim above $20 (about a recovery to 15% margins).
S · Story
- Thesis: a leading protein-shake brand has a temporary margin squeeze. Price rises and easing costs bring EBITDA back toward $350M+, debt falls, and the equity is worth well above today's price.
- Three things that must stay true: (1) Premier Protein volume holds after double-digit price rises; (2) key retailers keep the shelf space; (3) net debt/EBITDA falls below 3x within two years.
- Inversion: bear case: Fairlife and private label take the category, retailers push back on price, and the 12% margin is the new normal with $1.1B of debt. Rebuttal: ROIC and growth history show real demand. Concession: pricing power hasn't been proven since the squeeze.
- Sell triggers (if owned): FY27 EBITDA guide below $275M; Premier volume down after the price rise; net debt above 4x EBITDA; loss of a top-two retail customer; debt-funded buybacks.
Markers
- ?
roic_consistent: no 10-year series; ROIC ≥10% in every year available (2018–25). Likely ✔. - ✔
roic_not_falling: 3-year average is 125% of the 10-year average. - ?
growth_coherent: not enough years. - ✔
margin_stable: spread 1.9 points over the available history. Caution: the latest quarters have fallen, so this will probably fail next year. - ✘
fcf_margin: 9.6% vs 10%. Confirmed, borderline. - ✔
cash_real: 1.31. - ✘
low_debt: 5.0 years of FCF. Confirmed: the main weakness. - ✘
no_dilution: the +27% share growth reflects the 2022 spin-off, not ongoing issuance. Override: partly ✔ since 2023 (134M → 128M). - ?
predictable: revenue rose every year shown (1.0). - ?
recession_tested: no 2020 data (pre-spin).
Numbers
| Item | Screen | My view |
|---|---|---|
| Sticker / MOS | $42.60 / $21.30 | Not reached: assumes 15% growth; EPS is falling this year |
| Payback | $30.10 | Based on TTM FCF $225M; trough FCF is lower |
| Ten Cap | $15.09 | ≈ $5 on trough FCF (see above) |
| Windage growth | 15% | Street: −52% this year, +27% next: cut to ~5% until margins recover |
| P/E vs 10-yr median | 6.0 vs 32.9 | Median is inflated by early years; TTM EPS $1.42 will fall |
| Owner earnings | $286.6M | Before FY26 margin cut |
| Net debt | $1,085M | ≈ 3.8x guided EBITDA (midpoint) |
| Cash conversion | 1.31 |
| FY | Revenue $M | EPS | OCF $M | FCF $M | ROIC % |
|---|---|---|---|---|---|
| 2020 | 988 | 0.60 | 97 | 95 | n/a |
| 2021 | 1,247 | 0.70 | 226 | 225 | n/a |
| 2022 | 1,372 | 0.88 | 21 | 19 | 30.6 |
| 2023 | 1,667 | 1.23 | 216 | 214 | 40.5 |
| 2024 | 1,996 | 1.86 | 200 | 198 | 46.3 |
| 2025 | 2,317 | 1.68 | 261 | 256 | 42.4 |
No deep-dive model exists.
Sources
- BellRing Q3 FY2026 earnings release, 8-K (SEC)
- BellRing Q3 earnings call highlights (MarketBeat, 4 Aug 2026)
- BellRing Q3 FY2026 earnings summary (Quartr)
Figures came from search summaries; the 10-K, proxy and customer concentration were not read. The date of the Q4 release and what caused the 76% fall: not found.
Changelog
- 2026-10-10: created. WATCH: good brand, margin squeeze, 3.8x leverage; screen prices not accepted.